vedolizumab + vaccine

Vedolizumab is a humanized monoclonal antibody targeting the `α4β7 integrin`, which mediates lymphocyte trafficking to the gut, thereby reducing gastrointestinal inflammation in diseases such as ulcerative colitis and Crohn's disease. It is administered intravenously or subcutaneously. Vaccines are biological preparations that stimulate the immune system to develop immunity against specific infectious agents. The combination "vaccine + vedolizumab" refers to the concurrent or sequential use of vaccines with vedolizumab treatment, particularly relevant because vedolizumab selectively modulates gut immune responses and may affect vaccine efficacy or safety profiles. Live vaccines are generally not recommended during vedolizumab therapy due to potential infection risk, although non-live vaccines like influenza and COVID-19 vaccines are considered safe. Vedolizumab does not broadly suppress systemic immunity but targets gut-specific integrins, which may influence vaccination strategies in patients receiving this drug[1][2][4][6].